LLY ▼ -2.0% - Eli Lilly and Company
$LLY - Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study
30-SEP-2026 06:00 PM ET
Share this post
More filings for $LLY
LLY ▲ +4.6% - Eli Lilly and CompanyOct 20, 2026LLY ▼ -1.4% - Eli Lilly and CompanyOct 19, 2026LLY ▲ +0.4% - Eli Lilly and CompanyOct 18, 2026LLY ▲ +3.8% - Eli Lilly and CompanyOct 15, 2026LLY ▲ +1.3% - Eli Lilly and CompanyOct 15, 2026LLY ▲ +3.5% - Eli Lilly and CompanyOct 14, 2026
View full $LLY filing history →💬 Comments
Loading comments…
Leave a comment